Human Insulin Like Growth Factor-2 Recombinant

/, CD markers, IGF family, Recombinant Human Cytokines/Human Insulin Like Growth Factor-2 Recombinant

Human Insulin Like Growth Factor-2 Recombinant

$70.00$1,700.00


accession P01344


Source Optimized DNA sequence encoding Insulin Like Growth Factor-2mature chain was expressed in Escherichia Coli.
Molecular weight Native human Insulin Like Growth Factor-2 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately7 kDa. RecombinantIGF-2 is a monomer protein consisting of68 amino acid residue subunits, and migrates as an approximately7 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity >97%, as determined by SDS-PAGE and HPLC
Biological Activity The ED(50) was determined by the proliferation ofFDC-P1 cells and was found to be is ≤.0 ng/ml, corresponding to a specific activity of ≥1 x units/mg.
Protein Sequence MGIPMGKSML VLLTFLAFAS CCIAAYRPSE TLCGGELVDT LQFVCGDRGF YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS E RDVSTPPTV LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR EAKRHRPLIA LPTQDPAHGG APPEMASNRK
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Recombinant IGF-2 was lyophilized from a.2 μm filtered PBS solution pH.5.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.


Interactor P08833
Interactor P11717
Interactor P17936 IBP3_HUMAN
Biological Process Carbohydrate-metabolism
Biological Process Osteogenesis
Molecular function Growth-factor
Molecular function Hormone
Molecular function Mitogen

Methods

IGF2 infusion reduces the number of Aβ40 and Aβ42 plaques in the hippocampus.

human recombinant IGF2
  • IGF2 treatment significantly reduced the number of hippocampal plaques as determined by one-way ANOVA with repeated measures [A, F(1,10) = 6.987, p = 0.027; B, F(1,10) = 6.483, p = 0.029].

BMP and FGF are robust trophic factors for purified astrocytes.

100 ng/ml IGF2
  • 5 ng/ml HbEGF (positive control), as well as 100 ng/ml BMP5, 100 ng/ml IGF2 and 10 ng/ml FGF2 each significantly increase astrocyte viability above control .